Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Jun;8(2):371-385.
doi: 10.1002/epi4.12695. Epub 2023 Feb 14.

Frequency of and factors associated with antiseizure medication discontinuation discussions and decisions in patients with epilepsy: A multicenter retrospective chart review

Affiliations
Multicenter Study

Frequency of and factors associated with antiseizure medication discontinuation discussions and decisions in patients with epilepsy: A multicenter retrospective chart review

Samuel W Terman et al. Epilepsia Open. 2023 Jun.

Abstract

Objective: Guidelines suggest considering antiseizure medication (ASM) discontinuation in patients with epilepsy who become seizure-free. Little is known about how discontinuation decisions are being made in practice. We measured the frequency of, and factors associated with, discussions and decisions surrounding ASM discontinuation.

Methods: We performed a multicenter retrospective cohort study at the University of Michigan (UM) and two Dutch centers: Wilhelmina Children's Hospital (WCH) and Stichting Epilepsie Instellingen Nederland (SEIN). We screened all children and adults with outpatient epilepsy visits in January 2015 and included those with at least one visit during the subsequent 2 years where they were seizure-free for at least one year. We recorded whether charts documented (1) a discussion with the patient about possible ASM discontinuation and (2) any planned attempt to discontinue at least one ASM. We conducted multilevel logistic regressions to determine factors associated with each outcome.

Results: We included 1058 visits from 463 patients. Of all patients who were seizure-free at least one year, 248/463 (53%) had documentation of any discussion and 98/463 (21%) planned to discontinue at least one ASM. Corresponding frequencies for patients who were seizure-free at least 2 years were 184/285 (65%) and 74/285 (26%). The probability of discussing or discontinuing increased with longer duration of seizure freedom. Still, even for patients who were 10 years seizure-free, our models predicated that in only 49% of visits was a discontinuation discussion documented, and in only 16% of visits was it decided to discontinue all ASMs. Provider-to-provider variation explained 18% of variation in whether patients discontinued any ASM.

Significance: Only approximately half of patients with prolonged seizure freedom had a documented discussion about ASM discontinuation. Discontinuation was fairly rare even among low-risk patients. Future work should further explore barriers to and facilitators of counseling and discontinuation attempts.

Keywords: antiseizure medication; decision-making; drug withdrawal; epilepsy.

PubMed Disclaimer

Conflict of interest statement

None of the authors has any conflict of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Frequency of planning to discontinue each antiseizure medication. There is one datapoint for each person‐medication taken at any point during 2015‐2017.
FIGURE 2
FIGURE 2
Adjusted probabilities and 95% confidence intervals of discussing or planning to discontinue any or all antiseizure medications (ASMs), stratified by a priori clinical variables. Each visit represented an observation.

Similar articles

Cited by

References

    1. Epilepsy: a public health imperative [Internet]. Geneva: World Health Organization; 2019. https://www.who.int/mental_health/neurology/epilepsy/report_2019/en/
    1. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30‐year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–86. - PMC - PubMed
    1. Hamilton KJ, Chen Z, Tomlin A, Kwan P. Mortality and morbidity of patients with treated and untreated epilepsy in New Zealand. Epilepsia. 2020;61(3):519–27. - PubMed
    1. Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study. Neurology. 2008;71(20):1572–8. - PubMed
    1. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet. 2012;11(September):792–802. - PubMed

Publication types

Substances